Alembic Pharmaceuticals wins final USFDA approval for key oncology drug; details insideAlembic Pharmaceuticals wins final USFDA approval for key oncology drug; details inside

Introduction

Leading pharmaceutical company receives USFDA approval for Methotrexate Injection USP in multi-dose and single-dose vials, expanding total ANDA approvals to 236.

Also Read: Jeena Sikho Lifecare partners with Sat Kartar Life to expand healthcare network; stock price up 4%

Share price movement of Alembic Pharmaceuticals

On April 16, 2026, Alembic Pharmaceuticals Ltd opened at ₹734.00, down 0.13% from its previous close of ₹734.95. The stock reached a high of ₹753.05 (2.47%) and a low of ₹733.10. By 15:01, it traded at ₹749.70, a 2.01% increase, with a market cap of ₹14,736.34 crore.

Alembic Receives USFDA Approval

Alembic Pharmaceuticals Limited received USFDA final approval for Methotrexate Injection USP. The approval covers multi-dose and single-dose vial strengths under Abbreviated New Drug Application.

The product is therapeutically equivalent to Hospira’s reference listed Methotrexate Injection. It is indicated for multiple cancer types including leukemia, lymphoma, osteosarcoma, breast cancer, and head and neck cancer.

It is also used for rheumatoid arthritis, juvenile idiopathic arthritis, and severe psoriasis treatment. Alembic now holds 236 ANDA approvals, including 218 final and 18 tentative approvals.

Stock performance of Alembic Pharmaceuticals for period of 1 week, 6 months, and 1 year

Alembic Pharmaceuticals Ltd delivered a 1-week return of 2.03%, a 6-month return of -21.7%, and a 1-year return of -13.8%.

Also Read: GAIL (India): Stock on radar after company to invest ₹3,800 Cr in 700 MW solar power projects

Shareholding pattern of Alembic Pharmaceuticals

Particulars	Mar 2026	Dec 2025	Sep 2025
Promoter	69.70%	69.70%	69.70%
FII	4.30%	4%	4.00%
DII	16.20%	16.20%	16.30%
Public	9.80%	10%	9.90%

About Alembic Pharmaceuticals

Alembic Pharmaceuticals Ltd (NSE: APLLTD) develops, manufactures, and markets formulations and APIs with multiple R&D centres and manufacturing facilities in India and globally.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs